Volume 124, Issue 3, Pages (March 2003)

Slides:



Advertisements
Similar presentations
Serum immunoglobulin a from patients with celiac disease inhibits human T84 intestinal crypt epithelial cell differentiation Tuula Halttunen, Markku Mäki.
Advertisements

Date of download: 6/25/2016 From: Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic.
Volume 131, Issue 2, Pages (August 2006)
Volume 46, Issue 3, Pages (March 2007)
Volume 54, Issue 4, Pages (October 1998)
Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen?  Patrick Marcellin, E. Jenny Heathcote,
Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection  Yi–Cheng Chen, I.–Shyan Sheen,
Hisashi Moriguchi, Makoto Kobayashi, Raymond T. Chung, Chifumi Sato 
Volume 117, Issue 1, Pages (July 1999)
Frank A. Anania, MD  The American Journal of Medicine 
Optimum timing of treatment for hepatitis C infection relative to liver transplantation  Dr Audrey Coilly, MD, Bruno Roche, MD, Prof Jean-Charles Duclos-Vallée,
Volume 44, Issue 4, Pages (April 2006)
Volume 131, Issue 2, Pages (August 2006)
Volume 147, Issue 1, Pages (July 2014)
Volume 131, Issue 2, Pages (August 2006)
Leptin, obesity, and liver disease
Covering the Cover Gastroenterology
Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals Liver Cancer - DOI: / Fig. 1. Flowchart of included.
Polyxeni Koutkia, Zhiren Lu, Tai C. Chen, Michael F. Holick 
Volume 123, Issue 6, Pages (December 2002)
Hepatitis B and C virus-related carcinogenesis
Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non- Cirrhotic Patients: A Societal Perspective  Gihan Hamdy Elsisi, MSc, PhD,
Is HCV Infection a Neurologic Disorder?
Psychiatric disorders among veterans with hepatitis C infection
Peginterferon alfa-2b plus ribavirin for chronic hepatitis
Liver transplantation for hepatitis B virus-related liver disease: Indications, prevention of recurrence and results  Bruno Roche, Didier Samuel  Journal.
Volume 120, Issue 2, Pages (February 2001)
Volume 124, Issue 4, Pages (April 2003)
Volume 41, Issue 3, Pages (September 2004)
Hepatitis B infection in heart transplant recipients
Michael Biermer, Thomas Berg  Gastroenterology 
Volume 123, Issue 4, Pages (October 2002)
Volume 41, Issue 3, Pages (September 2004)
Volume 120, Issue 3, Pages (February 2001)
Acute pancreatitis attributed to the use of interferon alfa-2b
Correction Journal of the American College of Surgeons
Jean-Michel Pawlotsky  Gastroenterology 
Incidence of Statin Hepatotoxicity in Patients With Hepatitis C
Volume 120, Issue 4, Pages (March 2001)
Volume 119, Issue 4, Pages (October 2000)
Volume 54, Issue 4, Pages (October 1998)
Volume 119, Issue 6, Pages (December 2000)
Volume 123, Issue 4, Pages (October 2002)
Hepatitis B and C virus-related carcinogenesis
Low-Dose Peginterferon Alfa-2a Is Safe and Produces a Sustained Virologic Response in Patients With Chronic Hepatitis C and End-Stage Renal Disease  Markus.
Lise L. Kjaergard, Sarah L. Frederiksen, Christian Gluud 
AGA technical review on nonalcoholic fatty liver disease
Psychiatric disorders among veterans with hepatitis C infection
Volume 123, Issue 4, Pages (October 2002)
Alan Bonder, MD, Nezam H. Afdhal, MD 
Volume 136, Issue 5, Pages e2 (May 2009)
AGA technical review on osteoporosis in gastrointestinal diseases
Volume 122, Issue 4, Pages (April 2002)
Liver Transplantation for Hepatocellular Carcinoma
Meta-analysis Shows Extended Therapy Improves Response of Patients With Chronic Hepatitis C Virus Genotype 1 Infection  Harald Farnik, Christian M. Lange,
Jia-Horng Kao*, Pei-Jer Chen*, Ming-Yang Lai*, Ding-Shinn Chen‡,§ 
Eldad S. Bialecki, Amobi M. Ezenekwe, Elizabeth M. Brunt, Brian T
Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection  Yi–Cheng Chen, I.–Shyan Sheen,
Volume 139, Issue 5, Pages (November 2010)
Hepatic deficiency of interleukin 10 in chronic hepatitis C
Scott K. Fung, Anna S.F. Lok  Clinical Gastroenterology and Hepatology 
Volume 117, Issue 3, Pages (September 1999)
Detection of HCV RNA in Sustained Virologic Response to Direct-Acting Antiviral Agents: Occult or Science Fiction?  Masaru Enomoto, Yoshiki Murakami,
Hisashi Moriguchi, Makoto Kobayashi, Raymond T. Chung, Chifumi Sato 
Controversies in Liver Transplantation for Hepatitis C
Volume 39, Issue 3, Pages (September 2003)
Volume 120, Issue 4, Pages (March 2001)
Volume 156, Issue 4, Pages (March 2019)
Induction Pegylated Interferon Alfa-2b in Combination With Ribavirin in Patients With Genotypes 1 and 4 Chronic Hepatitis C: A Prospective, Randomized,
Reversion of disease manifestations after HCV eradication
Presentation transcript:

Volume 124, Issue 3, Pages 642-650 (March 2003) Interferon-α 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: A randomized study  Didier Samuel, Thierry Bizollon, Cyrille Feray, Bruno Roche, Si Nafa Si Ahmed, Catherine Lemonnier, Marielle Cohard, Michel Reynes, Michelle Chevallier, Christian Ducerf, Jacques Baulieux, Michael Geffner, Janice K. Albrecht, Henri Bismuth, Christian Trepo  Gastroenterology  Volume 124, Issue 3, Pages 642-650 (March 2003) DOI: 10.1053/gast.2003.50095 Copyright © 2003 American Gastroenterological Association Terms and Conditions

Fig. 1 Flow chart of the selection process of the 2 groups of patients. HCC, hepatocellular carcinoma; ductopenia, loss of more than 25% interlobular bile ducts at screening biopsy. Gastroenterology 2003 124, 642-650DOI: (10.1053/gast.2003.50095) Copyright © 2003 American Gastroenterological Association Terms and Conditions

Fig. 2 Mean changes in serum HCV RNA from baseline expressed in log10 for patients treated with interferon alfa-2b plus ribavirin as well as control patients. The mean baseline value of HCV RNA in the treated and control groups was 6.81 ± 1.07 and 6.38 ± 0.81, respectively. The mean decrease in HCV RNA was −2.76 ± 1.58, −2.88 ± 1.86; −2.82 ± 2.16, and −1.38 ± 2.16, respectively, at weeks 12, 24, and 48 and at the end of follow-up. There was no change in mean HCV RNA levels in the control group (+0.02, −0.11, 0.00, and −0.25, respectively, at weeks 12, 24, and 48 and at the end of follow-up). The mean decrease in log10 HCV RNA level was significant at all time points (P < 0.0001 at all time points and P = 0.04 at the end of follow-up). ●, treatment; ○, control. Gastroenterology 2003 124, 642-650DOI: (10.1053/gast.2003.50095) Copyright © 2003 American Gastroenterological Association Terms and Conditions

Fig. 3 Mean changes in HCV RNA from baseline among patients treated with interferon alfa-2b plus ribavirin who were HCV RNA negative (●) and HCV RNA positive (○) at week 24. Gastroenterology 2003 124, 642-650DOI: (10.1053/gast.2003.50095) Copyright © 2003 American Gastroenterological Association Terms and Conditions